Biochemical termination of sustained fibrillation occurring after artificially induced ischemic arrest

Evaluation of the effectiveness of potassium chloride in the management of out-of hospital cardiac arrest by refractory ventricular fibrillation: Study protocol of the POTACREH study

PURPOSE

Out-of-hospital cardiac arrest (OHCA) has a poor prognosis, with an overall survival rate of about 5% at discharge. Shockable rhythm cardiac arrests (ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT)) have a better prognosis. In case of shockable rhythm, treatment is based on defibrillation, and thereafter, in case of failure of 3 external electric shocks (EES), on direct intravenous administration of 300 mg amiodarone, or lidocaine when amiodarone is unavailable or inefficient. During surgical procedures under extracorporeal circulation, a high potassium cardioplegia solution is administered to interrupt cardiac activity and facilitate surgical procedure. By extension, direct intravenous administration of potassium chloride (KCl) has been shown to convert VF, resulting in return to a hemodynamically efficient organized heart rate within a few minutes. The aim of this study is to provide clinical evidence that direct intravenous injection of KCl, into a patient presenting with OHCA due to refractory VF although 3 EES, should interrupt this VF and then allow rapid restauration of an organized heart rhythm, and thus return of spontaneous circulation (ROSC).

METHODS

A multicenter, prospective, single group, phase 2 study will be conducted on 81 patients presenting with refractory VF. After failure of 3 EES, each patient will receive direct intravenous injection of 20 mmol KCl instead of amiodarone. The primary outcome will be survival rate at hospital admission. Major secondary outcomes will include ROSC and time to ROSC in the prehospital setting, number of VF recidivism after KCl injection, survival rate at hospital discharge with a good neurologic prognostic, and survival rate 3 months after hospital discharge with a good neurologic prognostic.

RESULTS

No patient is currently included in the study.

DISCUSSION

Conventional guideline strategy based on antiarrhythmic drug administration, i.e. amiodarone or lidocaine, for OHCA due to shockable rhythm, has not yet demonstrated an increase in survival at hospital admission or at hospital discharge. This may be related to the major cardiodepressant effect of those drugs.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT04316611. Registered on March 2020. AP-HP180577 / N° EUDRACT: 2019-002544-24. Funded by the French Health Ministry. https://clinicaltrials.gov/ct2/show/NCT04316611.

The Effect of Prophylactic Intravenous Amiodarone Administration on Reperfusion Ventricular Fibrillation in Patients With Left Ventricular Hypertrophy Undergoing Cardiopulmonary Bypass Surgery: Protocol for a Randomized Double-Blind Clinical Trial

BACKGROUND

Ventricular fibrillation (VF) is a common arrhythmia that occurs after the release of aortic cross-clamp (ACC) in patients undergoing cardiopulmonary bypass (CPB) surgery. Repeated defibrillation and long duration of VF could increase myocardial injuries. In patients with left ventricular hypertrophy (LVH), VF is easier to occur and more difficult to be terminated. Amiodarone, known as class III antiarrhythmic agent, has the prominent properties of converting VF and restoring the sinus rhythm. Before ACC release, administration of amiodarone has been confirmed useful to reduce occurrence of VF. However, few studies are focused on the effect of amiodarone before ACC release on reducing VF in patients with LVH.

OBJECTIVE

This study aimed at determining the efficacy of prophylactic intravenous amiodarone administration on reperfusion VF after release of ACC in patients with LVH undergoing CPB surgery.

METHODS

This will be a prospective, randomized, double-blind, placebo-controlled trial. The trial will enroll 54 patients with LVH aged 18-75 years who will undergo CPB surgery. All eligible participants will be randomly allocated to either the amiodarone or placebo group by using the block randomization in a 1:1 ratio. The primary end point will be the incidence rate of VF 30 minutes after ACC release and be assessed using the Fisher exact test. All data will be analyzed in accordance with the intention-to-treat principle.

RESULTS

The study began in August 2022, and the data collection will take place for the next 2 academic years. As of this writing, 21 participants have already been recruited for the study.

CONCLUSIONS

With this trial, we are hoping to demonstrate that prophylactic infusion of amiodarone before ACC release could reduce the occurrence of reperfusion VF in patients with LVH.

TRIAL REGISTRATION

ClinicalTrials.gov ChiCTR2000035057; https://www.chictr.org.cn/showprojen.aspx?proj=57145.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)

DERR1-10.2196/40115.

Potassium-induced conversion of ventricular fibrillation after aortic declamping

OBJECTIVES

The anti-fibrillatory effect of potassium is well recognized from experimental models. There have, however, been very few clinical reports on the use of potassium to convert ventricular fibrillation (VF) after cardioplegic arrest.

METHODS

In total, 8465 adult patients undergoing cardiac operations on cardiopulmonary bypass (CPB) and with cold antegrade crystalloid cardioplegic arrest were consecutively enrolled in a database. Patients with VF after removal of the aortic clamp were given 20 mmol potassium, and if needed an extra 10 mmol, in the perfusion line and the conversion rate was registered. Preoperative and intraoperative factors possibly related to the occurrence of post-ischaemic VF were assessed.

RESULTS

Of these, 1721 (20%) patients had VF and 1366 of these (79%) were successfully treated with potassium infusion. Only 355 (21%) patients (4% of all operations) had direct-current countershock. The need for pacing was lower in the treatment group compared with the non-treatment group (P <0.001). Multivariate analysis revealed as the main findings that age, gender, amount of cardioplegia related to body mass index (BMI), and blood transfusion during the time of CPB had a highly significant (P <0.001) impact on reducing the rate of post-arrest VF. Somewhat contrary to expectation, left ventricular hypertrophy (LVH) was not a significant factor (P = 0.32) for post-arrest VF. No conversion by potassium was significant for age (P <0.001), gender (P <0.001) and LVH (P <0.001), but not for blood transfusion during CPB (P = 0.38) and for the ratio of cardioplegia-BMI (P = 0.26).

CONCLUSIONS

The results from this register study demonstrate that potassium infusion is an effective and convenient first-hand measure to convert post declamping VF on CPB.